UK markets closed
  • FTSE 100

    +45.88 (+0.65%)
  • FTSE 250

    +125.37 (+0.55%)
  • AIM

    +3.03 (+0.24%)

    +0.0009 (+0.07%)

    -0.0060 (-0.42%)

    +50.00 (+0.20%)
  • CMC Crypto 200

    -17.62 (-1.87%)
  • S&P 500

    +8.26 (+0.19%)
  • DOW

    +13.36 (+0.04%)

    +0.49 (+0.70%)

    -16.90 (-0.89%)
  • NIKKEI 225

    -9.83 (-0.03%)

    +103.25 (+0.36%)
  • DAX

    +122.05 (+0.78%)
  • CAC 40

    +54.17 (+0.83%)

Worldwide Regenerative Medicine Industry to 2030 - Market Analysis and Demand Forecasts

·6-min read

Dublin, June 01, 2021 (GLOBE NEWSWIRE) -- The "Regenerative Medicine Market Research Report: By Type (Cell Therapy, Gene Therapy, Tissue Engineered Products), Application (Musculoskeletal, Wound Care, Oncology, Dental, Ocular) - Global Industry Analysis and Demand Forecast to 2030" report has been added to's offering.

Over 17.9 million people die of cardiovascular diseases (CVDs) and 9.6 million of cancer each year, says the World Health Organization (WHO). With the mortality rate increasing every year, the global regenerative medicine market revenue is likely to grow to $39,012.0 million by 2030 from $8,186.9 million in 2019, at a 16.3% CAGR between 2020 and 2030.

This is because regenerative medicine is focused on repairing and recreating the tissues and cells destroyed by such diseases. In this regard, the regenerative medicine market is being driven by the rising geriatric population, as the elderly are more prone to chronic diseases than younger people. From 703 million in 2019, the number of people aged 65 and above around the world is set to reach 1.5 billion in 2050, as per the United Nations (UN).

The COVID-19 pandemic initially hurt the regenerative medicine market growth prospects, as most of the non-essential hospital departments were shut down and much of the staff was redirected to COVID care. However, the race to find a novel treatment for the infection has led to a massive increase in the demand for regenerative medicine, especially cell-based therapies, across the globe.

In the past, the regenerative medicine market was dominated by the cell therapy category, based on type. Due to the havoc being wreaked by the COVID-19 pandemic, the number of clinical trials involving cell therapies as a potential treatment has risen manifold in the past few months.

The musculoskeletal category, under the application segment of the regenerative medicine market, is predicted to witness the fastest growth in the coming years. With the rising geriatric population, the prevalence of orthopedic diseases is increasing. Since such diseases often result in the wastage of the muscle and bone, regenerative medicine is proving essential for patients to live a normal life, by helping restore the bone and muscle density.

In the years to come, the highest CAGR in the regenerative medicine market will be seen in the Asia-Pacific (APAC) region. Economic growth, surging private and public funding in medical research, rising incidence of chronic diseases, increasing population of the elderly, and growing medical tourism industry are driving the market in regional countries.

The most-significant companies in the global regenerative medicine market are 3M Company, Smith & Nephew plc, Integra LifeSciences Holdings Corporation, Stryker Corporation, Wright Medical Group N.V., Zimmer Biomet Holdings Inc., Amgen Inc., Novartis AG, Allergan plc, Organogenesis Holdings Inc., MiMedx Group Inc., Misonix Inc., Vericel Corporation, Takeda Pharmaceutical Company Limited, and Medtronic plc.

Key Topics Covered:

Chapter 1. Research Background

Chapter 2. Research Methodology

Chapter 3. Executive Summary

Chapter 4. Introduction
4.1. Definition of Market Segments
4.2. Market Dynamics
4.2.1 Trends Increasing number of collaborations and partnerships Evolution of the market with product launches
4.2.2 Drivers Technological advancements Increasing interest of government research institutes to establish regenerative medicine as a new medical discipline Rising prevalence of chronic diseases and genetic disorders Shifting demographics are creating higher burden of chronic diseases Involvement of various healthcare companies Increasing demand for organ transplantation Impact analysis of drivers on market forecast
4.2.3 Restraints Cost-ineffectiveness of regenerative medicine therapies Lack of attention from pricing and reimbursement authorities Limited access to stem cells Protection of intellectual property rights Safety and ethical issues surrounding stem cell-based therapy Impact analysis of restraints on market forecast
4.2.4 Opportunities Emerging economies are key opportunities area for market players
4.3. Impact of COVID-19
4.4. Porter's Five Forces Analysis

Chapter 5. Global Market Size and Forecast

Chapter 6. North America Market Size and Forecast

Chapter 7. Europe Market Size and Forecast

Chapter 8. APAC Market Size and Forecast

Chapter 9. LATAM Market Size and Forecast

Chapter 10. MEA Market Size and Forecast

Chapter 11. Competitive Landscape
11.1. Product Benchmarking of Key Players
11.2. Strategic Developments in the Market
11.2.1. Products Launches and Approvals
11.2.2. Acquisitions
11.2.3. Partnerships

Chapter 12. Company Profiles
12.1. Smith & Nephew plc
12.1.1 Business Overview
12.1.2 Product and Service Offerings
12.1.3 Key Financial Summary
12.2. 3M Company
12.2.1. Business Overview
12.2.2. Product and Service Offerings
12.2.3. Key Financial Summary
12.3. Integra LifeSciences Holdings Corporation
12.3.1. Business Overview
12.3.2. Product and Service Offerings
12.3.3. Key Financial Summary
12.4. Wright Medical Group N.V.
12.4.1. Business Overview
12.4.2. Product and Service Offerings
12.4.3. Key Financial Summary
12.5. Stryker Corporation
12.5.1. Business Overview
12.5.2. Product and Service Offerings
12.5.3. Key Financial Summary
12.6. Zimmer Biomet Holdings Inc.
12.6.1. Business Overview
12.6.2. Product and Service Offerings
12.6.3. Key Financial Summary
12.7. Novartis AG
12.7.1. Business Overview
12.7.2. Product and Service Offerings
12.7.3. Key Financial Summary
12.8. Amgen Inc.
12.8.1. Business Overview
12.8.2. Product and Service Offerings
12.8.3. Key Financial Summary
12.9. Allergan plc
12.9.1. Business Overview
12.9.2. Product and Service Offerings
12.9.3. Key Financial Summary
12.10. Medtronic plc
12.10.1. Business Overview
12.10.2. Product and Service Offerings
12.10.3. Key Financial Summary
12.11. MiMedx Group Inc.
12.11.1. Business Overview
12.11.2. Product and Service Offerings
12.12. Vericel Corporation
12.12.1. Business Overview
12.12.2. Product and Service Offerings
12.12.3. Key Financial Summary
12.13. Organogenesis Holdings Inc.
12.13.1. Business Overview
12.13.2. Product and Service Offerings
12.13.3. Key Financial Summary
12.14. Misonix Inc.
12.14.1. Business Overview
12.14.2. Product and Service Offerings
12.14.3. Key Financial Summary
12.15. Takeda Pharmaceutical Company Limited
12.15.1. Business Overview
12.15.2. Product and Service Offerings
12.15.3. Key Financial Summary

Chapter 13. Appendix

For more information about this report visit

CONTACT: CONTACT: Laura Wood, Senior Press Manager For E.S.T Office Hours Call 1-917-300-0470 For U.S./CAN Toll Free Call 1-800-526-8630 For GMT Office Hours Call +353-1-416-8900